London midday: PartyGaming jumps on bwin merger
29th Jul 2010 11:57
Company results have given traders plenty to ponder and shares are broadly higher, but online betting group PartyGaming is the star performer after announcing a merger with Austrian rival bwin. PartyGaming said the merger would create the world's largest listed online gaming business. Elsewhere i
Read moreEuropean midday: Earnings provide lift
29th Jul 2010 11:46
A bunch of forecast beating corporate results are giving Europe's leading exchanges a lift in midday dealings. Across the markets, the Dax in Frankfurt is up 37 points at 6,216, with the Cac in Paris 17 points higher at 3,688. The Swiss market has added 11 points at 6,288. Pharmaceutical firm Merc
Read moreBEFORE THE BELL: US Stock Futures Up Ahead Of Jobless Claims Data
29th Jul 2010 11:14
By Polya Lesova Stock futures pointed to opening gains on Wall Street Thursday, as strong earnings reports from European companies buoyed sentiment, with traders awaiting results from oil major Exxon Mobil Corp. and data on U.S. weekly jobless claims. Futures on the Dow Jones Industrial Ave
Read moreCORRECT: =UPDATE: AstraZeneca Ups Targets, Buybacks
29th Jul 2010 10:00
("=UPDATE: AstraZeneca Ups Targets, Buybacks; Brilinta Hopes Rise" published at 0829 GMT misstated the net profit figure. The same mistake occurred in an item published at 0635 GMT. The correct version follows:) By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--AstraZeneca PLC
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
29th Jul 2010 09:06
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0806 GMT [Dow Jones] AstraZeneca (AZN.LN) shares +4.1% at 3334p, with core 2Q results strong and guidance increased, notes Ev
Read moreMARKET TALK: AstraZeneca Soars Post 2Q; Evolution Keeps Sell
29th Jul 2010 09:06
0806 GMT [Dow Jones] AstraZeneca (AZN.LN) shares +4.1% at 3334p, with core 2Q results strong and guidance increased, notes Evolution Securities. Separately, the FDA panel backed broad Brilinta approval, Evolution adds, a positive for the stock. However, Evolution keeps at sell, with a 2850p target.
Read moreEuropean open: Earnings in focus
29th Jul 2010 09:00
Europe's main markets are cautiously higher in early dealings on Thursday as investors consider a bunch of corporate figures. Across the markets, the Dax in Frankfurt is up 14 points at 6,193, with the Cac in Paris 15 points higher at 3,686. The Swiss market has added 12 points at 6,289. France Te
Read moreLondon open: Astra leads advance
29th Jul 2010 08:49
London's blue chips are cautiously higher in early dealings on Thursday as investors consider a bunch of corporate figures. AstraZeneca is the best performer in early dealings. The group's potential blockbuster heart drug Brilinta has received the backing of a US advisory panel just as the drug gia
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
29th Jul 2010 08:03
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0703 GMT [Dow Jones] AstraZeneca (AZN.LN) earnings are a strong set, with FY core EPS guidance raised to $6.35-$6.65 from
Read moreMARKET TALK: AstraZeneca Numbers Strong;FY EPS Guidance Raised
29th Jul 2010 08:03
0703 GMT [Dow Jones] AstraZeneca (AZN.LN) earnings are a strong set, with FY core EPS guidance raised to $6.35-$6.65 from $6.05-$6.35, says Shore Capital. Adds the company has also increased its share buyback in 2010 to $2B from $1B, "catalysed we believe by a combination of the positive outcome of
Read moreAstraZeneca gets Brilinta boost, ups guidance
29th Jul 2010 07:48
AstraZeneca's potential blockbuster heart drug Brilinta has received the backing of a US advisory panel just as the drug giant increased 2010 earnings targets for a second time this year following a strong performance from emerging markets and key drugs in the second quarter. The US Food and Drug
Read moreMARKET TALK: AstraZeneca's Drug FDA Backing Seen Consistent
29th Jul 2010 07:37
0637 GMT [Dow Jones] AstraZeneca's (AZN.LN) backing by US FDA panel for the use of Brilinta, a proposed anti-clotting drug, was consistent with expectations, says UBS, though contrasted with "market concerns of a split panel, a narrow label, and/or requirements for more trials before US approval." A
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
29th Jul 2010 07:37
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0637 GMT [Dow Jones] AstraZeneca's (AZN.LN) backing by US FDA panel for the use of Brilinta, a proposed anti-clotting drug, w
Read morePRESS RELEASE: FDA Advisory Committee Recommends US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes
28th Jul 2010 23:50
WILMINGTON, Del., July 28 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic event
Read moreUPDATE: FDA Panel Backs Use Of AstraZeneca Anticlotting Drug Brilinta
28th Jul 2010 22:34
(Updates with FDA decision deadline, company comments.) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A U.S. Food and Drug Administration panel Wednesday backed the use of ticagrelor, a proposed anticlotting drug developed by AstraZeneca PLC (AZN, AZN.LN), de
Read more